Tag: title

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5^th-8^th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.

Gross Profit Increased 17% Year-Over-Year to $7.0 Million in 2025

Deutsche Lufthansa AG: Dr Johannes Teyssen, Acquisition

ARLINGTON, TX, June 03, 2026 (GLOBE NEWSWIRE) -- Greenway Technologies, Inc. (OTCQB: GWTI) (“Greenway”), an advanced gas-to-liquids (“GTL”) and gas-to-hydrogen (“GTH”) technology development company, announced that on May 28, 2026, Raymond Wright notified the Board of Directors (the “Board”) of Greenway of his resignation from his positions as a Board member and as Interim President of Greenway, effective on such date. In connection with his transition, the Board unanimously approved the conferral of the honorary title Chairman Emeritus in recognition of Mr. Wright’s long-standing leadership and foundational contributions to Greenway. The role of Chairman Emeritus is not a Board position and does not carry a vote.

Further clinical efficacy and pharmacology data also to be presented